Lower doses of human menopausal gonadotropin are associated with improved success with in vitro fertilization in women with low body weight.
Since previous data suggested hyperresponsiveness to human menopausal gonadotropin by women with low body weight, the daily dose was reduced to 1.5 ampules in patients undergoing in vitro fertilization weighing less than 55 kg. This allowed the extension of treatment to a minimum of 6 days. These changes were associated with improved results in in vitro fertilization in these women.